SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Savara Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.63+0.18 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.02 (+28.25%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.17B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.17
- Dividend yield
- –
- Free cash flow yield
- -9.43%
Fundamentals
- Net income
- -$139.31M
- EPS, diluted
- -$0.58
- Free cash flow
- -$110.66M
- Book value per share
- $0.57
- Diluted shares
- 254M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$143.63M
Net income
-$139.31M
EPS, diluted
-$0.58
Free cash flow
-$110.66M
Reported periodTrailing twelve months